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Background and aim: Altered glucose metabolism, oxidative stress, lipid levels and inflammatory markers are
important risk factors in diabetes, cardiovascular, and many other diseases. Cocoa has been shown to exert antioxidant
and anti-inflammatory effects. The aim of this study is twofold: to assess the effect of Cocoa on the lipid profile
and peroxidation in addition to the inflammatory markers in type 2 diabetic patients, and to represent a virtual
model of probable action mechanism of observed clinical effects of Cocoa consumption using in silico analysis
and bioinformatics data.
Methods: One hundred subjects with type 2 diabetes were included in a randomized clinical control trial. Fifty
treatment subjects received 10 grams cocoa powder and 10 grams milk powder dissolved in 250 ml of boiling
water, and the other fifty control subjects received only 10 grams milk powder dissolved in 250 ml boiling water.
Both groups were on the mentioned regimen twice daily for 6 weeks. Blood samples were obtained prior to
Cocoa consumption and 6 weeks after intervention. Serum lipids and lipoproteins profile, malondialdehyde and
inflammatory markers including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and high sensitive C-reactive
protein (hs-CRP) were measured. For statistical analysis two independent and paired samples
t-test and linear regression were used. Bioinformatics and virtual analysis were performed using string data base
and Molegro virtual software.
Results: Cocoa consumption lowered blood cholesterol,triglyceride, LDL-cholesterol, and TNF-α, hs-CRP, IL-6
significantly (P < 0.01). The results showed that the levels of HDL-cholesterol decreased significantly (P < 0.05) but
Cocoa inhibited lipid peroxidation in treatment group than control group (P < 0.0001). Virtual analysis showed that
the most frequent Cocoa ingredients, (+)-Catechin and (−)-Epicatechin, can dock to the enzyme COX-2.
Conclusion: These data support the beneficial effect of Cocoa on the lipid peroxidation prevention and inflammatory
markers in type 2 diabetic patients. Cocoa ingredients block the Cox-2 activation and reduce inflammatory prostanoids
synthesis according to virtual analysis.
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Insulin resistance and diabetes contributes to metabolic
disturbances [1]. Inflammation which occurs during im-
munological responses can also be regarded as a com-
plication resulting from a changed metabolism [2,3].
Moreover, the main risk factor for diabetic patient’s
death is cardiovascular disease (CVD). Although CVD-
caused mortality has decreased since the past decades,
it still accounts for higher than 40% of the total mortal-
ity rate [4]. CVD is widely asserted to be associated
with elevated oxidative stress [5]. Lipid peroxidation is
the most commonly assessed process in oxidative stress
research. There are various plasma markers of lipid
peroxidation including Malondialdehyde, lipid hydro-
peroxides, conjugated dienes, oxidation resistance assay
(lag time), oxysterols and F2α-isoprostanes [6]. Histor-
ically, the most common method for measuring lipid
peroxidation has been the thiobarbituric acid reactive
substances (TBARS) assay to quantify malondialdehyde
[6]. Although increased risk of coronary artery disease
(CAD) has contributed to hyperglycemia, dyslipidemia
and thrombotic state, recent studies have come to focus
on inflammatory markers [7]. Markers of chronic low-
grade inflammation, such as tumor necrosis factor-α
(TNF-α), Interleukin-6 (IL-6), and high sensitive- C-react-
ive protein (hs-CRP) have been shown to predict the risk
of developing type 2 diabetes and cardiovascular disease.
Moreover, they are conceived to be directly involved in
the pathogenesis of such chronic diseases [8]. TNF-α and
IL-6 belong to cytokines which are predominantly se-
creted from adipose tissues while hs-CRP is the principal
downstream mediator of the acute phase response and is
secreted by the liver in response to TNF-α and IL-6 [9].
Nutrition plays a key role in the prevention of many
chronic diseases including CVD, cancers, diabetes, and
inflammatory diseases [10]. Cocoa is known to be rich in
polyphenols, such as catechin, epicatechin, procyanidin B2
(dimer), procyanidin C1 (trimer), cinnamtannin A2 (tetra-
mer), and other oligomer procyanidins [11]. Studies on
healthy human subjects have indicated decreased levels
of serum LDL-cholesterol and increased levels of HDL-
cholesterol. Furthermore, resistance of LDL-cholesterol to
oxidation following the intake of dairy Cocoa powder has
been reported previously [12,13]. In vitro studies have sug-
gested that Cocoa procyanidins and phenolic metabolites
can also modify intracellular signal transduction pathways
thereby modulating the synthesis of inflammatory cyto-
kine such as IL-6 [14].
Prostaglandin synthase-2 (PTGS-2) which is mostly
defined as cyclooxygenase-2 (COX-2) enzyme, is respon-
sible for the production of the prostaglandins following
inflammation. Activation of PTGS-2 results in the rate
limiting step in inflammatory prostaglandins produc-
tion [15] and it is induced after activation of cytokines,mitogens and endotoxins. Its transcription is potentially
activated following inflammation induction in inflamma-
tory cells [16]. Computational biology and bioinformatics
studies are helpful to explore probable interactions of bio-
molecules with chemicals such as herbal active ingredients
at least in the case of the absence of real models, such as
pure in vitro models.
Phenolic ingredients of Cocoa exert potent antioxidant
properties in-vitro. Flavanols and flavonoids founded in
tea and Cocoa shown to have anti-oxidant and anti-
inflammatory effects such as platelet activation inhibition
[17]. Different actions have been reported for Cocoa in-
gredients, ie., slowing down LDL-oxidation [18,19] and
reducting inflammatory cytokines synthesis [20] modula-
tion of TNF-α secretion from mononuclear blood cells
[21]. However, exact molecular mechanism of such actions
is not clearly identified. The aim of this study is to evaluate
the effect of 6-week regimen of cocoa consumption on
lipid profile,lipoproteins peroxidation and inflammatory
markers including TNF-α, IL-6 and hs-CRP in a random-
ized controlled clinical trial. Moreover, using an in silico
simulation, probable interactions of PTGS-2/COX-2 with
two most frequent phytochemical ingredients of Cocoa,
(+)-Catechin and (−)-Epicatechin are evaluated. This
contributes to address whether the active ingredient of
Cocoa target inflammation-inducer enzymes is COX-2
and whether this is the probable mechanism of Cocoa
ingredient anti-inflammatory action.Materials and methods
One hundred subjects affected with type 2 diabetes par-
ticipated in the study. Patients were from the data base
of Yazd Diabetes research center who were selected by a
simple sampling method. The eligibility criteria were as
follows: age between 40–70 years; total cholesterol
above 240 mg/dl; triglyceride higher than 200 mg/dl; no
regular consumption of supplements affecting lipid me-
tabolism; no extreme exercise habits; and no history of
any anti-hyperlipidemia drugs usage. Study participants
were informed about the research status and only those
who approved and verified the consent form were in-
cluded. Moreover, the study situations and ethical con-
firmation were determined by the ethic committee of
Shahid Sadoughi University of Medical Sciences. The
trial has been registered in Iranian Registry of Cilinical
Trials at http://www.irct.ir with the following identifi-
cation: IRCT201101265697NI. Virtual analysis was per-
formed using Molegro Virtual Docker Software Ver. 4.2.
Furthermore, interactive network was obtained from
STRING data base. Protein data bank was also another
data base to explore the properties and characteristics
of Prostaglandin Synthase-2 (PTGS-2/COX-2) enzyme.
Cheminformatics structures of active ingredients of Cocoa,
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data base as well.
Experimental design
One hundred type 2 diabetic patients were randomly di-
vided into two categories of 50 individuals. Fifty patients
were assigned to the treatment group (TG) and instructed
to consume 10 grams cocoa powder added to 10 grams
dried milk powder both dissolved in 250 ml boiling water.
The regimen, daily twice, continued for 6 weeks. The con-
trol group (CG) was also instructed to use only 10 grams
of milk powder dissolved in 250 ml of boiling water with
the same regimen period as the other group (twice daily
for 2 weeks). The regimen would have to be applied before
noon and during afternoon. To make sure that the speci-
fied regimen foods would be consumed by all the subjects,
arrangements were made to supply home deliveries of
packaged powder to each subject 1 week prior to con-
sumption until the termination of the study. Furthermore,
clear guidance was represented based on the need of the
subjects to maintain their routine diets for breakfast,
lunch, drinks, incidental foods and therapeutic drugs regi-
men. In addition, in order to check that the normal diets
would be maintained, the subjects’ complete dietary re-
cords throughout the study were kept. The subjects were
also advised to avoid taking any supplements and all other
cocoa products and to lead their usual life style through-
out the study. Blood samples were then obtained from
all volunteers prior to Cocoa consumption and 6 weeks
after intervention. Blood cholesterol, triglycerides and
HDL-cholesterol (HDL-C) were measured by enzymatic col-
orimetric kit methods (Pars Azmun Co.) according to pack-
age insert instructions. Low density lipoprotein cholesterol
(LDL-C) was calculated using Friedewald formula [22].
Malondialdehyde, ie end product of lipid peroxidation,
levels were measured by thiobarbituric acid reactive sub-
stances (TBARS) Method [23]. Three inflammatory markersTable 1 Comparison of serum levels of lipids, lipoproteins an
control categories before and after intervention; Under treat
regimen but control individuals were only under milk powde
Biochemical indices Categories Before intervention mean ±
Total cholesterol Treatment 246.22 ± 4.14
(mg/dl) Control 242 ± 11.6
Triglyceride Treatment 226 ± 10.15
(mg/dl) Control 232.7 ± 10.04
HDL-cholesterol Treatment 35.06 ± 2.53
(mg/dl) Control 33.2 ± 2.49
LDL-cholesterol Treatment 135.08 ± 3.15
(mg/dl) Control 135.72 ± 7.56
MDAx1000 Treatment 71.32 ± 0.55
(nmol) Control 53.4 ± 0.62such as hs-CRP, IL6 and TNF-α serum levels were also mea-
sured by a sandwich ELISA methods (Diazyme Co.).
Statistical analysis
The data were analyzed by SPSS package Version 13.
Statistical analysis was performed using the independent
and paired samples t-test. Pearson correlation coefficient
was also applied for correlation estimation between mal-
ondialdehyde and inflammatory markers. P-values were
considered significant at <0.05.
Virtual analysis and bioinformatics data
In silico experiment was performed in a virtual interactive
environment using Molegro Virtual Docking Software Ver.
4.2. COX-2 X-ray crystallographic and ligand structures
were obtained from protein data bank [Protein Data Bank
(PDB) ID code 6COX] and Zinc Cheminformatics data
base [24]. Docking method was energy minimization the
results of which were obtained according to the MolDock
scores. Bioinformatics data from protein data bank were
also accessed. Cheminformatics structures were (+)-Cat-




The ratio of males to females was the same in both
groups. The patient’s mean age was 54 ± 5 and the mean
score for body mass index (BMI) was 28 ± 5 kg/m2.
Table 1 illustrates the comparison of serum lipids, lipo-
proteins and malondialdehyde of the treatment and con-
trol groups before and after the intervention. Data analysis
for comparison between the groups before and after a 6-
week intervention (Figure 1) detects that total cholesterol,
triglyceride, HDL-C, LDL-C and MDA are changed sig-
nificantly only in TG: 16.57% total cholesterol reduction
in TG, P < 0.0001 vs. 5.08% reduction in CG, P = 0.0006;d MDA in type 2 diabetic patients of treatment and
ment individuals were under Cocoa plus milk powder
r regimen, both groups, for 6 weeks





















Figure 1 Comparaison of biochemical markers of lipid profile and lipid peroxidation between treatment and control categories.
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CG, P = 0.0009; 7.58% reduction of HDL-C in TG, P =
0.0003 vs. 4.57% in CG, P = 0.0258; 17.54% reduction of
LDL-C in TG, P < 0.0001 vs. 2.57% in CG, P = 0.1308; mal-
ondialdehyde levels, however, were not reduced signifi-
cantly in TG (0.45%, P = 0.787) but increased significantly
in CG (17.75%, P < 0.0001).
As presented in Table 2, after 6 weeks of Cocoa pow-
der consumption, there were significant decreases for
serum levels of hs-CRP, IL-6, and TNF-α respectively
(CI = 0.95, P < 0.05). Moreover, the results revealed a
positive correlation between malondialdehyde and in-
flammatory markers (hs-CRP, IL-6, TNF-α) which is sta-
tistically significant (P < 0.05) (Table 3).
Bioinformatics data and virtual analysis results
Prostaglandin synthase-2 (PTGS-2/COX-2) belongs to
the peroxidase protein family. According to the string
data base there are more than 50 other proteins that
have possibly no interaction with or effect on the COX-
2/PTGS-2. However, an interactive network obtained
from string data base suggests that PTGS-2 is affected
by, or even exerts influence on Tumor Necrosis Factor
alpha (TNF-α), Interlukin-6 (IL-6), Interlukin-1B (IL-1B),
Toll Like receptors (TLR), prostaglandins, cell signaling
mediators, activators and so forth. As it is shown inTable 2 Blood level of inflammatory markers in type 2 diabet




consumption (Mean ± SD)
hs-CRP (mg/dl) 0.43 ± 0.32
IL-6 (pg/ml) 2.5 ± 0.9
TNF-α (pg/ml) 2.64 ± 0.95Figure 2, PTGS-2 is activated by TNF-α and IL6 path-
ways; both molecules were measured in our interven-
tional clinical study. Figure 3 shows coexpression of
PTGS-2 with proteins of Figure 2 network; this figure
implies that PTGS-2 is mostly coexpressed concurrently
with IL1B, IL8 and IL6. Therefore, for investigation
of inflammation, increment of IL8 and IL1B may be ob-
vious in addition to IL6. Figure 4 depicts an X-ray crys-
tallographic structure of PTGS-2.
Docking results
Docking studies of (+)-Catechin and (−)-Epicatechin
with PTGS-2 resulted in good interactions, as schemat-
ically shown in the Figure 5, depicting the best sites of
protein-ligand interaction sites; Catechin interacts with
PTGS-2 in various positions but mostly with the interface
domains of two chains. As the scoring criteria of docking
is on the basis of MolDock score and is reported as repre-
sentative of Gibbs free energy (delta-G), therefore, the
more negative the mean score, the better interaction value
and status. Interaction of ligand-acceptor is scored accord-
ing to the MolDock score in Molegro Virtual Docker soft-
ware. In the present in silico analysis, the best score is
−135.315 for Catechin and in a position that ten hydrogen
bounds (shown as blue color in Figure 5) among amino
acids Tyrosine 373, Serine 121 and 126, Phenylalanine 367ic patients before consumption of Cocoa plus milk and
After cocoa powder
consomption (Mean ± SD)
P-value
0.23 ± 0.31 0.0294
1.7 ± 0.7 0.001
1.38 ± 0.28 <0.0001
Table 3 Correlation table of malondialdehyde and
inflammatory markers hs-CRP, IL-6, TNF-α
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Leucine 344, Isoleucine 124, and Glutamine 369. Another
important and interesting interaction is one of Catechin/
Epicatechin with Heme prosthetic group of PTGS-2 that
is scored according to the MolDock score equal to
−131.715 in the best status for Catechin interaction with
Heme prosthetic group. Anyway, Epicatechin interacts
with Heme by a score equal to −126.31. However, this lat-
est noted interaction in fact is the best interaction of
Epicatechin-PTGS-2.
Discussion
The protective effect of dietary flavonoids against many
diseases in particular cardiovascular disease and diabetes
are supported by several studies [12,13,25-28]. Cocoa is a
rich source of polyphenols. The flavan-3-ol monomers,
catechin, epicatechin, and the oligomeric procyanidins are
the major flavonoids in Cocoa [25]. Attention has been di-
rected to the antioxidant potential of these flavonoids ofFigure 2 Prostaglandine synthase-2 (PTGS-2) interactive network obta
proteins were the score more than 0.98% relevancies.Cocoa and their potentially protective effects against the
risk of cardiovascular disease [17,25,26,29]. In the current
study, our results have shown favorable effects on serum
lipids and lipoprotein concentrations in type 2 diabetic pa-
tients after 6 weeks of Cocoa consumption. Also in this
study we have addressed whether a 6-week consumption
of Cocoa produces a beneficial effect on blood lipid pe-
roxidation. Our results show that consumption of Cocoa
significantly reduces serum levels of total cholesterol,
triglyceride, HDL-C and LDL-C in type 2 diabetic pa-
tients after 6 weeks. Previous studies have reported that
polyphenol-rich Cocoa and chocolate reduce LDL-C in
humans [13,25]. Baba S. et al. detected that consump-
tion of 26 grams/day of Cocoa powder for 12 weeks
lowers plasma LDL-C by 11% in healthy men [12]. This
report supports our finding on LDL-C. Other studies
have also reported that polyphenol-rich dark chocolate
and Cocoa powder increases plasma HDL-cholesterol
[12,13,25-28]. Wan et al. have identified that after daily
consumption of 22 g of Cocoa powder for 4 weeks, the
concentration of HDL-cholesterol was 4% higher fol-
lowing a control diet [26]. These findings suggest that
absorbed polyphenolic substances in Cocoa powder,
such as Catechin and Epicatechin, may affect plasma
HDL-C concentration. In our study, however, HDL-C
concentrations decreased significantly in both treatment
and control groups; such effect may be due to theined from string data base. The criteria for screening showed
Figure 3 This figure shows coexpression of 20 selected proteins. PTGS-2 is mostly coexpressed concurrently with IL1B, IL8 and IL6.
Figure 4 Quaternary structure of PTGS-2 depicted in Molegro Virtual Docker software. 2 Heme groups which are prosthetic groups are
located in the active site of enzyme. Also structures of (+)-Catechin and (−)-Epicatechin are depicted in Chimera software; the atoms of Catechin
and Epicatechin are shown by: oxygen in red color, hydrogen in white and the else are carbon.
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Figure 5 Interaction of Cocoa most frequent ingredients Catechin and Epicatechin with PTGS-2/COX-2; A: depicts interaction of Catechin
with PTGS-2 in the position with the highest score according to the MolDock score. B: depicts the interaction Catechin/ Epicatechin with
Heme prosthetic group of PTGS-2 (−131.715); C: depicts a rough shape of PTGS-2 interaction with Catechin molecule and its steric position;
D: depicts Catechin (left) and Epicatechin (right) interaction with Heme prosthetic groups.
Parsaeyan et al. Journal of Diabetes & Metabolic Disorders 2014, 13:30 Page 7 of 9
http://www.jdmdonline.com/content/13/1/30changes of dietary regimen in study population and the
effect of milk and Cocoa lipoprotein and lipid contents
which may change the type of lipids of diabetic patients.
Moreover, consumption of Cocoa has been found to in-
hibit lipid peroxidation in treatment group; malondial-
dehyde concentrations in type 2 diabetic patients who
were on the Cocoa regimen did not change significantly
but increased in patients bereft of Cocoa supplement.
As some studies have shown that consumption of Cocoa
decreases the formation of lipid oxidation products
such as malondialdehyde [28,29], and in line with our
results, we propose that such impact is more preventive
than lowering. Decreased rates of lipid peroxidation in
diabetic patients after Cocoa administration suggest
that such effects may be due to flavonoids contents of
Cocoa.
Inflammation plays a pivotal role in cardiovascular
events. Studies suggest that lifestyle and drug interven-
tions which reduce hs-CRP levels typically delay and
decrease the risk of cardiovascular diseases [30,31].
However, there is a limited number of controlled study
to define the effects of individual dietary constituents
on biomarkers of inflammation [32]. Mathur et al. have
shown no significant change in whole-blood cytokines,
IL-6, TNF-α and hs-CRP after 6 weeks of Cocoa sup-
plementation [33]. However, the results of our studyrevealed that serum level of TNF-α, IL-6 and hs-CRP
decreases significantly in patients under Cocoa powder
regimen. The correlation between malondialdehyde and
inflammatory markers (hs-CRP, IL-6, TNF-α) indicated
that a significant positive correlation exists between them.
Considering such inflammatory markers, it could be sug-
gested that Cocoa flavonoids represent an exciting new
area of nutritional research especially as a cardiovascular
damage protective agents in diabetic patients. Anyway,
further experimental studies with Cocoa flavonoids are re-
quired to define the specific mechanisms of action on the
inflammatory markers. Long-term studies with large sam-
ple sizes are also warranted to determine optimal doses
and long-term effects of flavonoids, including Cocoa.
However, bioinformatics and docking analysis were
helpful for exploring some potential evidences of observed
effects of Cocoa consumption which may be addressed as
the following: a) As shown in Figure 2, PTGS-2 inflamma-
tory enzyme is activated by TNF-α, IL6, IL1B, TLR and so
forth, then inhibition of inflammation by Cocoa ingre-
dients is probable especially via inhibition of PTGS-2,
as is expected according to in silico/docking analysis
which catalyses the production of inflammatory prosta-
noids. Therefore, inductive effect and responses of in-
flammatory cytokines such as TNF-α, IL6, IL1B, IL8
and prostaglandins all became obstructed by inhibition
Figure 6 Conceptual map depicted according to the virtual analysis and clinical results from our interventional study. Inflammatory
cytokines induce activation of PTGS-2 via signal transduction pathways.
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coexpression with IL8, IL1B and IL6. So it is likely that
not only TNF-α and IL6 but also other more valuable
agents involved in inflammation processes may exist.
Different types of proteins, therefore, could be targeted
by ligands such as Catechin and Epicatechin. In view of
the fact that inflammation induces lipid peroxidation
[34,35] and regarding that PTGS-2 has a main role in
production of inflammatory prostanoids, it is proposed
that decreased level of serum total cholesterol, Triglyc-
erides, LDL-cholesterol, and inhibition of malondial-
dehyde formation after 6-week Cocoa consumption
(Table 1) be all related to the interaction and probably
inhibition of PTGS-2 by Catechin and Epicatechin.
Such event, according to the virtual analysis, results in
beneficial effects on lipid and lipoprotein metabolism
and potentially via unknown ways. Furthermore, de-
creased levels of inflammatory markers TNF-α, IL6 and
hs-CRP may also be related to the probable interaction
of Catechin and Epicatechin with signaling molecules in
the pathways inducing such markers production thus
requiring more investigations. Another interesting find-
ing of docking result is the interaction of Catechin/Epi-
catechin with prosthetic groups of PTGS-2. PTGS-2 has
two groups of Heme. Heme is the prosthetic group and
then a part of enzyme active site. Regarding the fact that
binding of a ligand to the active site of an enzyme could
halt catalytic activity, we propose that the interaction ofCocoa ingredients such as Catechin/Epicatechin with
PTGS-2 is accomplished via Heme, which in turn, re-
sults in the inhibition of the enzyme, reduction of the
inflammation and the manifestation of the results we
have reported in our clinical experiments. Altogether, a
conceptual diagram based on the virtual and clinical
results can be proposed as in Figure 6. According to
Figure 6 we thus can propose Cocoa or its active ingredi-
ents as anti-inflammatory agents that their mechanism of
action, for example signaling molecules mediators, should
be precisely described and unraveling aspects of this calls
for further research.
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